Safety of MF59™ adjuvant

Abstract

The need to enhance the immunogenicity of purified subunit antigens has prompted the development of new adjuvants. The adjuvant emulsion MF59 has been tested in animals in combination with different antigens and finally evaluated in humans. It was licensed after the successful outcome of preclinical and clinical testing. This paper summarizes the main characteristics of the MF59 adjuvant, including animal testing, clinical experience with various vaccines, and information from current postmarketing surveillance data. This review supports the hypothesis that MF59 is a safe adjuvant for human use.

Journal

Title: Vaccine

Abbreviated Title: Vaccine

Publisher: Elsevier BV

ISSN (Print): 0264410X

Publication date Created: June 2008

Publication date (Print): June 2008

Volume: 26

Issue: 26

Pages: 3209-3222

Article

DOI: 10.1016/j.vaccine.2008.03.093

PubMed ID: 18462843

SO-VID: 303ae65a-1d5c-4844-b038-01e39415adb9

Copyright statement: © 2008

License:

https://www.elsevier.com/tdm/userlicense/1.0/

Product

Self URI (article page): https://linkinghub.elsevier.com/retrieve/pii/S0264410X08003861